MRK, SGP getting hammered on Vytorin/Zetia efficacy data

New England Journal of Medicine study concluded that while Vytorin reduces cholesterol, it does not reduce the risk of heart disease.

"You've just seen a negative trial that should change practice, especially the way we in this country have prescribed" the drugs, Yale University cardiologist Harlan Krumholz told thousands of cardiologists. He urged doctors to go "back to statins," the class of cholesterol-lowering drugs that includes Lipitor and Zocor. Major studies have demonstrated their ability to save lives and prevent heart attacks.

Shares of MRK are down over 10% in extended trading.
SGP is poised to open 20% lower.